Larimar Therapeutics, Inc.
METHODS OF QUANTIFYING FRATAXIN AND FRATAXIN FUSION PROTEINS

Abstract:

The present disclosure provides methods for determining the amount of FXN or FXN fusion protein in a sample, e.g, a tissue sample, by using mass spectrometry.